clinical trial · NCT01946074
A Study of ABT-165 in Subjects With Solid Tumors
AbbVie·phase1·completed·n = 101
Advanced Solid TumorspaclitaxelFOLFIRIABT-165ABBV-181
brief summary
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-165 when administered as monotherapy and in combination with paclitaxel or 5-fluoruracil, folinic acid and irinotecan (FOLFIRI) or ABBV-181 with/without paclitaxel in subjects with advanced solid tumors. Enrollment to Cohorts A, B were completed and for Cohorts C and D are recruiting.
started
Aug 8, 2013
primary completion
Sep 28, 2022
completion
Sep 28, 2022
last updated
Dec 15, 2023
official title
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol